LifeCell Reports Fourth Quarter and Full Year 2007 Financi...( PRODUCT REVENUES UP 35...),Health

PRODUCT REVENUES UP 35% VERSUS FULL YEAR 2006

BRANCHBURG, N.J., Feb. 27 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC) today reported financial results for the fourth quarter and full year ended December 31, 2007. Paul Thomas, President and Chief Executive Officer, will host a conference call today at 10:00 a.m. Eastern to discuss the fourth quarter and full year financial results.

Fourth Quarter 2007 Results

Product revenues for the fourth quarter were $52.6 million, up 34%, compared to $39.3 million reported for the same period in 2006. The increase in product revenue was primarily due to an increase in demand for the Company's flagship reconstructive surgical product, AlloDerm(R) Regenerative Tissue Matrix, which increased 38% to $46.9 million in the current quarter compared to $33.9 million in the fourth quarter of 2006. Orthopedic product revenues, which include GraftJacket(R) and AlloCraft(TM)DBM, increased 13% to $3.1 million in the quarter from $2.8 million in the fourth quarter of 2006. Repliform(R) revenues decreased in the quarter to $1.9 million from $2.1 million in the same quarter in 2006.

Operating income for the fourth quarter of 2007 decreased 1% to $9.3 million compared to operating income of $9.4 million in the fourth quarter of 2006. Operating income in the fourth quarter of 2007 was negatively impacted by higher than normal legal fees and the previously announced settlement of a non-product related claim.

Net income for the fourth quarter of 2007 was $5.5 million, or $0.16 per diluted share, compared to net income of $6.2 million, or $0.18 per diluted share in the fourth quarter of 2006. The settlement noted above reduced diluted net income per share by appr
'/>"/>